A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines

被引:18
作者
Zhang, L. [1 ]
Guelses, A. [2 ]
Purcz, N. [2 ]
Weimer, J. [3 ]
Wiltfang, J. [2 ]
Acil, Y. [2 ]
机构
[1] Zhejiang Univ, Stomatol Hosp, Dept Oral & Maxillofacial Surg, Hangzhou, Zhejiang, Peoples R China
[2] Univ Kiel, Dept Oral & Maxillofacial Surg, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany
[3] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany
关键词
Squamous cell carcinoma; Primary culture cell; Cell line; Proliferation; Integrin; Cilengitide; PHASE-I; GLIOBLASTOMA; CETUXIMAB; 5-FLUOROURACIL; CHEMOTHERAPY; COMBINATION; CISPLATIN; ADHESION; GROWTH; CANCER;
D O I
10.1007/s12094-018-02025-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIntegrins are highly attractive targets in oncology due to their involvement in angiogenesis in a wide spectrum of cancer entities. Among several integrin inhibitors, cilengitide is suggested to be one of the most promising inhibitors. However, little is known about the cellular processes induced during cilengitide chemotherapy in head and neck squamous cell carcinoma (HNSCC).Materials and methodsFor the current study, 3 HNSCC cell lines, SCC4, SCC15 and SCC25; and 3 primary culture cells, TU53, TU57, and TU63 were used. CD90, cytokeratin, and vimentin were stained immunohistochemically to identify the biological characteristics of these cell lines and primary culture cells and the cytostatic effect of cilengitide was evaluated. Quantitative polymerase chain reaction (qPCR) arrays were applied to evaluate target protein genes ITGAV, ITGB3, and ITGB5 of integrin alpha v beta 3 and alpha v beta 5 at respective concentrations of 50 and 100 mu M cilengitide for 72h.ResultsCilengitide has significantly inhibited the proliferation of HNSCC cells in a dose-dependent way. At the same concentration, cilengitide suppressed the proliferation of primary culture cells even more strongly than it did that of cell lines, suggesting that primary culture cells retain more of their internal biological characteristics than do cell lines. qPCR assay detected downregulation of ITGAV, ITGB3, and ITGB5 gene expression after exposure to 50 mu M of cilengitide. However, after exposure to 100-mu M cilengitide, expression of these genes significantly increased both in cell lines and primary culture cells.ConclusionsRGD-containing small-molecule synthetic peptides might be considered in tumor chemotherapy in the near future. The different reactions of primary culture cells and cell lines demonstrated that individualized chemotherapy plans may be a feasible option. However, research on the role of cilengitide in HNSCC therapy is still in its early stages, and further investigations are required.
引用
收藏
页码:1052 / 1060
页数:9
相关论文
共 26 条
[1]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[2]   Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro [J].
Arul, Melanie ;
Roslani, April Camilla ;
Cheah, Swee Hung .
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2017, 53 (05) :435-447
[3]   Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients [J].
Cedra, Susan ;
Wiegand, Susanne ;
Kolb, Marlen ;
Dietz, Andreas ;
Wichmann, Gunnar .
CANCERS, 2017, 9 (09)
[4]   Screening for distant metastases in patients with head and neck cancer [J].
de Bree, R ;
Deurloo, EE ;
Snow, GB ;
Leemans, CR .
LARYNGOSCOPE, 2000, 110 (03) :397-401
[5]   The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer [J].
Denaro, N. ;
Russi, E. G. ;
Colantonio, I. ;
Adamo, V. ;
Merlano, M. C. .
ONCOLOGY, 2012, 83 (02) :108-116
[6]   Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression [J].
Eisele, Gunter ;
Wick, Antje ;
Eisele, Anna-Carina ;
Clement, Paul M. ;
Tonn, Jorg ;
Tabatabai, Ghazaleh ;
Ochsenbein, Adrian ;
Schlegel, Uwe ;
Neyns, Bart ;
Krex, Dietmar ;
Simon, Matthias ;
Nikkhah, Guido ;
Picard, Martin ;
Stupp, Roger ;
Wick, Wolfgang ;
Weller, Michael .
JOURNAL OF NEURO-ONCOLOGY, 2014, 117 (01) :141-145
[7]   Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas [J].
Fabricius, Eva-Maria ;
Wildner, Gustav-Paul ;
Kruse-Boitschenko, Ute ;
Hoffmeister, Bodo ;
Goodman, Simon L. ;
Raguse, Jan-Dirk .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (01) :9-19
[8]   A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma [J].
Gerstner, Elizabeth R. ;
Ye, Xiaobu ;
Duda, Dan G. ;
Levine, Michael A. ;
Mikkelsen, Tom ;
Kaley, Thomas J. ;
Olson, Jeffrey J. ;
Nabors, Burt L. ;
Ahluwalia, Manmeet S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. ;
Batchelor, Tracy T. ;
Grossman, Stuart .
NEURO-ONCOLOGY, 2015, 17 (10) :1386-1392
[9]  
Heiduschka G, 2014, STRAHLENTHER ONKOL, V190, P472, DOI 10.1007/s00066-014-0600-x
[10]   αVβ6 is a novel receptor for human fibrillin-1 -: Comparative studies of molecular determinants underlying integrin-RGD affinityand specificity [J].
Jovanovic, Jelena ;
Takagi, Junichi ;
Choulier, Laurence ;
Abrescia, Nicola G. A. ;
Stuart, David I. ;
van der Merwe, P. Anton ;
Mardon, Helen J. ;
Handford, Penny A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (09) :6743-6751